VolitionRx Targets Licensing Deals Amid Financial Rebound
With first-half revenue climbing 112% to $1.4 million, VolitionRx is shifting its commercial strategy toward aggressive licensing negotiations. The epigenetics firm is currently courting over a dozen global diagnostic companies, aiming to turn its proprietary liquid biopsy and cancer-detection technologies into recurring royalty streams and milestone payments.
CEO Cameron Reynolds confirmed that the company is actively evaluating partnerships to scale its reach, focusing on its core product pillars. While second-quarter revenue held steady at approximately $0.4 million, the firm significantly tightened its financial belt, cutting operating expenses by 32% compared to the same period last year. This discipline reduced the quarterly operating loss to $4.2 million, an improvement of 34% year-over-year.
Technological milestones underpin the company's current valuation, which management estimates represents a multi-billion-dollar opportunity. Key developments include a pending clinical manuscript for the Nu.Q Vet feline lymphoma assay, which could trigger a $5 million milestone payment upon publication. Simultaneously, the company is working with the Hospices Civils de Lyon to secure reimbursement for its Nu.Q Lung Cancer test, a critical step toward routine clinical adoption. To bolster liquidity, VolitionRx successfully raised $5.3 million in the second quarter through equity sales and a public offering of shares and warrants.
Comments (0)
No comments yet. Be the first!